DexCom (NASDAQ: DXCM) recently received a number of ratings updates from brokerages and research firms:

  • 9/1/2017 – DexCom was upgraded by analysts at ValuEngine from a “sell” rating to a “hold” rating.
  • 8/22/2017 – DexCom had its “buy” rating reaffirmed by analysts at Canaccord Genuity. They now have a $90.00 price target on the stock.
  • 8/19/2017 – DexCom was upgraded by analysts at BidaskClub from a “sell” rating to a “hold” rating.
  • 8/16/2017 – DexCom had its “overweight” rating reaffirmed by analysts at Piper Jaffray Companies. They now have a $78.00 price target on the stock, down previously from $87.00.
  • 8/14/2017 – DexCom was upgraded by analysts at Zacks Investment Research from a “sell” rating to a “hold” rating. According to Zacks, “DexCom reported narrower-than-expected loss in the second quarter. We believe the company’s margins will continue to be under pressure in the coming quarters, owing to high product development costs and rising expenditures on research & development. Specifically, the company is expected to have lower margins on transmitter sales (in spite of the cost reduction initiatives). Additionally, cutthroat competition in the market for blood glucose monitoring devices is a major headwind. In the past one year, DexCom has underperformed the broader industry in terms of price. On the positive side, the glucose monitoring market represents significant commercial opportunity for DexCom. The company has also signed collaborative agreements with several companies, which should not only bring in cash, but also help expand its product portfolio.”
  • 8/9/2017 – DexCom was upgraded by analysts at BidaskClub from a “strong sell” rating to a “sell” rating.
  • 8/8/2017 – DexCom had its “outperform” rating reaffirmed by analysts at BMO Capital Markets. They now have a $90.00 price target on the stock, down previously from $105.00.
  • 8/4/2017 – DexCom was downgraded by analysts at Zacks Investment Research from a “hold” rating to a “sell” rating. According to Zacks, “DexCom reported narrower-than-expected loss in the second quarter. We believe the company’s margins will continue to be under pressure in the coming quarters, owing to high product development costs and rising expenditures on research & development. Specifically, the company is expected to have lower margins on transmitter sales (in spite of the cost reduction initiatives). Additionally, cutthroat competition in the market for blood glucose monitoring devices is a major headwind. In the past one year, DexCom has underperformed the broader industry in terms of price. On the positive side, the glucose monitoring market represents significant commercial opportunity for DexCom. The company has also signed collaborative agreements with several companies, which should not only bring in cash, but also help expand its product portfolio.”
  • 8/2/2017 – DexCom was given a new $92.00 price target on by analysts at Oppenheimer Holdings, Inc.. They now have a “buy” rating on the stock.
  • 8/2/2017 – DexCom had its “overweight” rating reaffirmed by analysts at Stephens. They now have a $83.00 price target on the stock, down previously from $95.00.
  • 8/2/2017 – DexCom had its “outperform” rating reaffirmed by analysts at BMO Capital Markets. They now have a $90.00 price target on the stock, down previously from $105.00.
  • 8/2/2017 – DexCom was upgraded by analysts at TheStreet from a “d” rating to a “c-” rating.
  • 8/1/2017 – DexCom was downgraded by analysts at BidaskClub from a “sell” rating to a “strong sell” rating.
  • 7/24/2017 – DexCom was downgraded by analysts at BidaskClub from a “hold” rating to a “sell” rating.
  • 7/18/2017 – DexCom was upgraded by analysts at Zacks Investment Research from a “sell” rating to a “hold” rating. According to Zacks, “In the past one year, DexCom has underperformed the broader industry in terms of price. Furthermore, a disappointing estimate revision trend indicates looming concerns ahead. DexCom reported narrower-than-expected loss in the first quarter. We believe the company’s margins will continue to be under pressure in the coming quarters owing to high product development costs and rising expenditures on research & development. Specifically, the company is expected to have lower margins on transmitter sales (in spite of the cost reduction initiatives). Additionally, cutthroat competition in the market for blood glucose monitoring devices is a major headwind. On the positive side, the glucose monitoring market represents significant commercial opportunity for DexCom. The company has also signed collaborative agreements with several companies, which should not only bring in cash but also help expand its product portfolio.”
  • 7/14/2017 – DexCom had its “buy” rating reaffirmed by analysts at Cowen and Company. They now have a $90.00 price target on the stock.
  • 7/13/2017 – DexCom had its “buy” rating reaffirmed by analysts at BMO Capital Markets. They now have a $105.00 price target on the stock.
  • 7/12/2017 – DexCom had its “buy” rating reaffirmed by analysts at Piper Jaffray Companies. They now have a $78.00 price target on the stock.

Shares of DexCom, Inc. (DXCM) traded down 0.95% during trading on Wednesday, reaching $75.13. 1,554,549 shares of the company’s stock traded hands. The company’s market capitalization is $6.50 billion. DexCom, Inc. has a 1-year low of $57.68 and a 1-year high of $96.38. The stock has a 50-day moving average of $71.69 and a 200-day moving average of $74.36.

DexCom (NASDAQ:DXCM) last issued its earnings results on Tuesday, August 1st. The medical device company reported ($0.16) earnings per share (EPS) for the quarter, topping the Thomson Reuters’ consensus estimate of ($0.23) by $0.07. DexCom had a return on equity of 3.68% and a net margin of 1.70%. The firm had revenue of $170.60 million for the quarter, compared to analysts’ expectations of $166.54 million. During the same period in the previous year, the firm posted ($0.24) earnings per share. The business’s revenue was up 24.3% compared to the same quarter last year. On average, equities analysts predict that DexCom, Inc. will post ($0.77) EPS for the current fiscal year.

In other DexCom news, CEO Kevin R. Sayer sold 6,000 shares of the business’s stock in a transaction that occurred on Monday, June 12th. The stock was sold at an average price of $69.07, for a total transaction of $414,420.00. The sale was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. Also, EVP Andrew K. Balo sold 3,200 shares of the business’s stock in a transaction that occurred on Monday, June 12th. The stock was sold at an average price of $69.06, for a total value of $220,992.00. The disclosure for this sale can be found here. Insiders sold 32,179 shares of company stock worth $2,282,217 over the last ninety days. Insiders own 1.70% of the company’s stock.

Dexcom, Inc (Dexcom) is a medical device company. The Company is focused on the design, development and commercialization of continuous glucose monitoring (CGM) systems for ambulatory use by people with diabetes and for use by healthcare providers. The Company’s products consist of DexCom G4 PLATINUM and DexCom G5 Mobile.

Receive News & Stock Ratings for DexCom Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for DexCom Inc and related stocks with our FREE daily email newsletter.